1 Growth Stock With 741% Upside, According to Wall Street

Shares of biotech Novavax (NASDAQ: NVAX) have plunged 91% in the past year as the company has struggled to make its mark in the coronavirus vaccine market. Novavax's lack of success in this space is even more troubling, considering global COVID-19 vaccine sales will drop substantially starting this year, so even the leaders in the field have struggled of late. While it seems highly unlikely that Novavax will soar by that much anytime soon, perhaps the broader question is whether there's a substantial upside ahead for the company.